Market ExpansionThe label expansion into 1L maintenance should provide meaningful growth driven by expansion into a larger patient pool in the earlier line along with a longer duration of therapy.
Oncology Drug DevelopmentImproved performance for Rylaze is expected following updates to the pediatric oncology protocol.
Regulatory ApprovalZepzelca in combination with Tecentriq was granted priority review for 1L maintenance therapy in extensive-stage small cell lung cancer (ES-SCLC), with a PDUFA date set for October 7, following positive survival benefit demonstrated in the Phase 3 IMforte data, which seems encouraging and likely to be approved for the new indication.